CSIMarket
 


Co diagnostics Inc   (CODX)
Other Ticker:  
 
 

CODX's Capital Expenditures Growth by Quarter and Year

Co Diagnostics Inc 's Capital Expenditures results by quarter and year




CODX Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 0.46 0.29 0.12 0.47
III Quarter September 0.24 0.23 0.17 0.10
II Quarter June 0.48 0.51 0.24 0.10
I Quarter March 0.18 0.40 0.14 0.10
FY   1.36 1.43 0.67 0.77



CODX Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Co diagnostics Inc reported Capital Expenditures surge of 60.21% year on year in the fourth quarter 2023, to $ 0.46 millions, this is lower than Co Diagnostics Inc 's recent average Capital Expenditures rise of 76.62%.

Looking into fourth quarter 2023 results within Medical Equipment & Supplies industry 27 other companies have achieved higher Capital Expenditures growth. While Co Diagnostics Inc ' s Capital Expenditures jump of 60.21% ranks overall at the positon no. 652 in the fourth quarter 2023.




CODX Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 60.21 % 141.67 % -74.47 % 1075 %
III Quarter September 4.35 % 35.29 % 70 % 400 %
II Quarter June -5.88 % 112.5 % 140 % 100 %
I Quarter March -55 % 185.71 % 40 % -
FY   -4.57 % 113.43 % -12.99 % 600 %

Financial Statements
Co Diagnostics Inc 's fourth quarter 2023 Capital Expenditures $ 0.46 millions CODX's Income Statement
Co Diagnostics Inc 's fourth quarter 2022 Capital Expenditures $ 0.29 millions Quarterly CODX's Income Statement
New: More CODX's historic Capital Expenditures Growth >>


CODX Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 93.58 % 26.09 % -29.41 % 370 %
III Quarter September -50 % -54.9 % -29.17 % 0 %
II Quarter June 166.67 % 27.5 % 71.43 % 0 %
I Quarter March -37.93 % 233.33 % -70.21 % 150 %
FY (Year on Year)   -4.57 % 113.43 % -12.99 % 600 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #28
Healthcare Sector #76
Overall #652

Capital Expenditures Y/Y Growth Statistics
High Average Low
280.86 % 76.62 % -13.55 %
(Mar 31 2021)   (Dec 31 2021)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #28
Healthcare Sector #76
Overall #652
Capital Expenditures Y/Y Growth Statistics
High Average Low
280.86 % 76.62 % -13.55 %
(Mar 31 2021)   (Dec 31 2021)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Co Diagnostics Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
366.88 % 27.96 % -100 %
(Dec 31 2020)  


CODX's IV. Quarter Q/Q Capital Expenditures Comment
Co diagnostics Inc achieved in the IV. Quarter 2023 above company average sequential Capital Expenditures jump of 93.58%, to $ 0.46 millions, from $0.24 millions in the third quarter.
Co Diagnostics Inc is going from strength to strength, not just recording higher then average gain, and additionally improving speed.

Within Medical Equipment & Supplies industry 16 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Co Diagnostics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 274.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #17
Healthcare Sector #52
Overall #274
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #17
Healthcare Sector #52
Overall #274
Capital Expenditures Q/Q Growth Statistics
High Average Low
366.88 % 27.96 % -100 %
(Dec 31 2020)  


CODX's IV. Quarter Q/Q Capital Expenditures Comment
Co diagnostics Inc achieved in the IV. Quarter 2023 above company average sequential Capital Expenditures jump of 93.58%, to $ 0.46 millions, from $0.24 millions in the third quarter.
Medical Equipment & Supplies company is impressively improving, not only claiming above average increase, and also improving pace.

Within Medical Equipment & Supplies industry 16 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Co Diagnostics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 274.


Co Diagnostics Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 1.37 $ 1.19 $ 1.19 $ 1.21 $ 1.43
Y / Y Capital Expenditures Growth (TTM) -4.36 % -4.93 % -0.35 % 30.69 % 113.23 %
Year on Year Capital Expenditures Growth Overall Ranking # 106 # 880 # 826 # 965 # 127
Seqeuential Capital Expenditures Change (TTM) 14.35 % 0.55 % -1.93 % -15.18 % 13.66 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 652 # 1258 # 754 # 631 # 1131




Cumulative Capital Expenditures growth Comment
Co Diagnostics Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Sep 30 2023. If the fiscal year would end in Dec 31 2023, Co Diagnostics Inc 's annual Capital Expenditures growth would be -4.36% year on year to $1 millions.

Among companies within the Healthcare sector 16 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 106, from total ranking in previous quarter at 880.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
280.86 %
76.62 %
-13.55 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 28
Healthcare Sector # 17
Overall # 106

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
280.86 %
76.62 %
-13.55 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 76
S&P 500 # 652
Cumulative Capital Expenditures growth Comment
Co Diagnostics Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Sep 30 2023. If the fiscal year would end in Dec 31 2023, Co Diagnostics Inc 's annual Capital Expenditures fall would be -4.36% year on year to $1 millions.

Among companies within the Healthcare sector 16 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 106, from total ranking in previous quarter at 880.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
280.86 %
76.62 %
-13.55 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 28
Healthcare Sector # 17
Overall # 106

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
280.86 %
76.62 %
-13.55 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 76
S&P 500 # 652




Other Capital Expenditures Growth
Medical Equipment & Supplies Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
CODX's Capital Expenditures Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for CODX's Competitors
Capital Expenditures Growth for Co Diagnostics Inc 's Suppliers
Capital Expenditures Growth for CODX's Customers

You may also want to know
CODX's Annual Growth Rates CODX's Profitability Ratios CODX's Asset Turnover Ratio CODX's Dividend Growth
CODX's Roe CODX's Valuation Ratios CODX's Financial Strength Ratios CODX's Dividend Payout Ratio
CODX's Roa CODX's Inventory Turnover Ratio CODX's Growth Rates CODX's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
United Therapeutics Corporation99.24%$ 99.241 millions
Zymeworks Inc 98.64%$ 98.641 millions
Proqr Therapeutics N v 93.64%$ 93.644 millions
National Research Corporation91.76%$ 91.760 millions
Irhythm Technologies Inc 90.57%$ 90.568 millions
Tandem Diabetes Care Inc 88.36%$ 88.360 millions
Agilon Health Inc 85.12%$ 85.125 millions
Schrodinger Inc 84.18%$ 84.175 millions
Dynatronics Corporation83.55%$ 83.547 millions
Nautilus Biotechnology Inc 80.35%$ 80.349 millions
Elanco Animal Health Inc77.22%$ 77.215 millions
Arrowhead Pharmaceuticals Inc 76.44%$ 76.444 millions
Renovaro Inc 75.96%$ 75.957 millions
Neuronetics inc 74.75%$ 74.751 millions
Integra Lifesciences Holdings Corp69.72%$ 69.722 millions
Bausch and Lomb Corp68.00%$ 68.000 millions
Entera Bio Ltd 66.67%$ 66.667 millions
Perrigo Company Plc65.84%$ 65.839 millions
Regeneron Pharmaceuticals Inc 65.18%$ 65.177 millions
Anaptysbio Inc 60.00%$ 60.000 millions
Cadre Holdings Inc 59.32%$ 59.319 millions
Co diagnostics Inc 58.40%$ 58.403 millions
Macrogenics Inc 57.76%$ 57.761 millions
Caribou Biosciences Inc 56.28%$ 56.280 millions
Privia Health Group Inc 53.33%$ 53.333 millions
National Healthcare Corp52.58%$ 52.581 millions
Ani Pharmaceuticals Inc52.10%$ 52.101 millions
Avantor Inc 50.60%$ 50.595 millions
Bausch Health Companies Inc 50.00%$ 50.000 millions
Gh Research Plc49.25%$ 49.254 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com